FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317434128> ?p ?o ?g. }

• W4317434128 endingPage "422" @default.
• W4317434128 startingPage "410" @default.
• W4317434128 abstract "Abstract Background Current models of levodopa (L ‐dopa)‐induced dyskinesia (LID) are obtained by treating dopamine‐depleted animals with L ‐dopa. However, patients with LID receive combination therapies that often include dopamine agonists. Objective Using 6‐hydroxydopamine‐lesioned rats as a model, we aimed to establish whether an adjunct treatment with the D2/3 agonist ropinirole impacts on patterns of LID‐related neuroplasticity and drug responses. Methods Different regimens of L ‐dopa monotreatment and L ‐dopa‐ropinirole cotreatment were compared using measures of hypokinesia and dyskinesia. Striatal expression of ∆FosB and angiogenesis markers were studied immunohistochemically. Antidyskinetic effects of different drug categories were investigated in parallel groups of rats receiving either L ‐dopa monotreatment or L ‐dopa combined with ropinirole. Results We defined chronic regimens of L ‐dopa monotreatment and L ‐dopa‐ropinirole cotreatment inducing overall similar abnormal involuntary movement scores. Compared with the monotreatment group, animals receiving the L ‐dopa‐ropinirole combination exhibited an overall lower striatal expression of ∆FosB with a distinctive compartmental distribution. The expression of angiogenesis markers and blood–brain barrier hyperpermeability was markedly reduced after L ‐dopa‐ropinirole cotreatment compared with L ‐dopa monotreatment. Moreover, significant group differences were detected upon examining the response to candidate antidyskinetic drugs. In particular, compounds modulating D1 receptor signaling had a stronger effect in the L ‐dopa‐only group, whereas both amantadine and the selective NMDA antagonist MK801 produced a markedly larger antidyskinetic effect in L ‐dopa‐ropinirole cotreated animals. Conclusions Cotreatment with ropinirole altered LID‐related neuroplasticity and pharmacological response profiles. The impact of adjuvant dopamine agonist treatment should be taken into consideration when investigating LID mechanisms and candidate interventions in both clinical and experimental settings. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society." @default.
• W4317434128 created "2023-01-19" @default.
• W4317434128 creator A5003872696 @default.
• W4317434128 creator A5020001161 @default.
• W4317434128 creator A5021352250 @default.
• W4317434128 creator A5030011548 @default.
• W4317434128 creator A5085357435 @default.
• W4317434128 date "2023-01-19" @default.
• W4317434128 modified "2023-10-14" @default.
• W4317434128 title "Dopamine Agonist Cotreatment Alters Neuroplasticity and Pharmacology of <scp>Levodopa</scp>‐Induced Dyskinesia" @default.
• W4317434128 cites W1798056883 @default.
• W4317434128 cites W1964830694 @default.
• W4317434128 cites W1971698832 @default.
• W4317434128 cites W1991935832 @default.
• W4317434128 cites W1993079687 @default.
• W4317434128 cites W1998818358 @default.
• W4317434128 cites W1999401390 @default.
• W4317434128 cites W2004875858 @default.
• W4317434128 cites W2015851905 @default.
• W4317434128 cites W2050269602 @default.
• W4317434128 cites W2054281268 @default.
• W4317434128 cites W2075121314 @default.
• W4317434128 cites W2079606458 @default.
• W4317434128 cites W2102668445 @default.
• W4317434128 cites W2107495925 @default.
• W4317434128 cites W2112682964 @default.
• W4317434128 cites W2118555630 @default.
• W4317434128 cites W2127460667 @default.
• W4317434128 cites W2136632794 @default.
• W4317434128 cites W2138389486 @default.
• W4317434128 cites W2149958198 @default.
• W4317434128 cites W2155760129 @default.
• W4317434128 cites W2159726703 @default.
• W4317434128 cites W2162284422 @default.
• W4317434128 cites W2169384441 @default.
• W4317434128 cites W2176383114 @default.
• W4317434128 cites W2177243354 @default.
• W4317434128 cites W2518506345 @default.
• W4317434128 cites W2770192564 @default.
• W4317434128 cites W2789545224 @default.
• W4317434128 cites W2799806408 @default.
• W4317434128 cites W2892880340 @default.
• W4317434128 cites W2936450015 @default.
• W4317434128 cites W3004815341 @default.
• W4317434128 cites W3063250637 @default.
• W4317434128 cites W3096102142 @default.
• W4317434128 cites W4221066485 @default.
• W4317434128 cites W4226327181 @default.
• W4317434128 cites W4239875825 @default.
• W4317434128 cites W4249936768 @default.
• W4317434128 doi "https://doi.org/10.1002/mds.29301" @default.
• W4317434128 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36656044" @default.
• W4317434128 hasPublicationYear "2023" @default.
• W4317434128 type Work @default.
• W4317434128 citedByCount "3" @default.
• W4317434128 countsByYear W43174341282023 @default.
• W4317434128 crossrefType "journal-article" @default.
• W4317434128 hasAuthorship W4317434128A5003872696 @default.
• W4317434128 hasAuthorship W4317434128A5020001161 @default.
• W4317434128 hasAuthorship W4317434128A5021352250 @default.
• W4317434128 hasAuthorship W4317434128A5030011548 @default.
• W4317434128 hasAuthorship W4317434128A5085357435 @default.
• W4317434128 hasBestOaLocation W43174341281 @default.
• W4317434128 hasConcept C126322002 @default.
• W4317434128 hasConcept C134018914 @default.
• W4317434128 hasConcept C15744967 @default.
• W4317434128 hasConcept C169760540 @default.
• W4317434128 hasConcept C170493617 @default.
• W4317434128 hasConcept C2777374534 @default.
• W4317434128 hasConcept C2777453868 @default.
• W4317434128 hasConcept C2778258207 @default.
• W4317434128 hasConcept C2778938600 @default.
• W4317434128 hasConcept C2779134260 @default.
• W4317434128 hasConcept C2779734285 @default.
• W4317434128 hasConcept C2780304432 @default.
• W4317434128 hasConcept C2780405171 @default.
• W4317434128 hasConcept C47611674 @default.
• W4317434128 hasConcept C513476851 @default.
• W4317434128 hasConcept C71924100 @default.
• W4317434128 hasConcept C98274493 @default.
• W4317434128 hasConceptScore W4317434128C126322002 @default.
• W4317434128 hasConceptScore W4317434128C134018914 @default.
• W4317434128 hasConceptScore W4317434128C15744967 @default.
• W4317434128 hasConceptScore W4317434128C169760540 @default.
• W4317434128 hasConceptScore W4317434128C170493617 @default.
• W4317434128 hasConceptScore W4317434128C2777374534 @default.
• W4317434128 hasConceptScore W4317434128C2777453868 @default.
• W4317434128 hasConceptScore W4317434128C2778258207 @default.
• W4317434128 hasConceptScore W4317434128C2778938600 @default.
• W4317434128 hasConceptScore W4317434128C2779134260 @default.
• W4317434128 hasConceptScore W4317434128C2779734285 @default.
• W4317434128 hasConceptScore W4317434128C2780304432 @default.
• W4317434128 hasConceptScore W4317434128C2780405171 @default.
• W4317434128 hasConceptScore W4317434128C47611674 @default.
• W4317434128 hasConceptScore W4317434128C513476851 @default.
• W4317434128 hasConceptScore W4317434128C71924100 @default.
• W4317434128 hasConceptScore W4317434128C98274493 @default.
• W4317434128 hasFunder F4320321999 @default.

• next